After Amgen’s KRAS confirmatory trial results were rejected by the FDA as uninterpretable, Bristol Myers Squibb has provided ...

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy ...

One of the biggest take-aways from our report is that LGBTQ+ people are probably at higher risk for cancer, yet experience ...

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much ...

Moderna's mRESVIA has secured FDA approval to protect adults ages 60 years and older from lower respiratory tract disease ...

In the span of half a year, Gilead’s Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer ...

While Canada’s largest vaccine manufacturing facility has opened its doors and is flying the Sanofi flag, another of the ...

As various efforts to produce next-generation vaccines in Africa are being carried forward by the likes of the World Health ...

Cytiva’s new platform rollout news came the same day Ori Biotech announced its IRO platform that automates, digitizes and ...

Gilead Sciences is drawing back the curtain on the Trodelvy lung cancer data that previously caused a 10% slide in the ...

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the ...

Amid a shortage of standard-of-care chemotherapy drugs, Sagent Pharmaceuticals is pulling two lots of its docetaxel injection ...